Results 41 to 50 of about 1,142,624 (314)

Posterior estimates of the effects covariables and credible interval on mean SMI prevalence estimated from full model.

open access: yes, 2022
Posterior estimates of the effects covariables and credible interval on mean SMI prevalence estimated from full model.
Guangquan Li (254103)   +6 more
core   +1 more source

Posterior log odds of childhood stunting and their 95% and 80% credible interval for the non-linear covariates.

open access: yes, 2022
Posterior log odds of childhood stunting and their 95% and 80% credible interval for the non-linear covariates.
Fiifi Amoako Johnson (7486028)
core   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

open access: yesMolecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic   +10 more
wiley   +1 more source

Application of Bayesian Analysis in Medical Diagnosis

open access: yesJournal of the Practice of Cardiovascular Sciences, 2019
In this work, we outlined the application of the Bayesian technique for integrating the results of multiple tests while treating any disease. We provided an overview of the fundamental concept of Bayesian analysis in making an inference about a ...
Vivek Verma   +2 more
doaj   +1 more source

Comparison of Bayesian and frequentist methods for prevalence estimation under misclassification

open access: yesBMC Public Health, 2020
Background Various methods exist for statistical inference about a prevalence that consider misclassifications due to an imperfect diagnostic test.
Matthias Flor   +4 more
doaj   +1 more source

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

open access: yesBMC Infectious Diseases, 2022
Background From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant.
Karan Pattni   +10 more
doaj   +1 more source

Solving the linear interval tolerance problem for weight initialization of neural networks [PDF]

open access: yes, 2014
Determining good initial conditions for an algorithm used to train a neural network is considered a parameter estimation problem dealing with uncertainty about the initial weights.
Adam, S.P.   +3 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Smoking and fracture risk in men: a meta-analysis of cohort studies, using both frequentist and Bayesian approaches

open access: yesScientific Reports, 2022
Past studies indicate that men are more likely to smoke and be at higher risk of smoking-related conditions than women. Our research aimed, through meta-analysis, to assess the association between smoking and fracture risk in men. The following databases
Yingke Xu   +3 more
doaj   +1 more source

Appendix B. Posterior mean and 95% credible interval for key model parameters.

open access: yes, 2016
Posterior mean and 95% credible interval for key model ...
Jan Ohlberger (571661)   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy